Literature DB >> 33301209

Adjuvant Osimertinib: A New Standard of Care.

Michael J Jelinek1, Charu Aggarwal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33301209      PMCID： PMC8018332          DOI： 10.1002/onco.13634

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  11 in total

1.  Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.

Authors:  Dongsheng Yue; Shidong Xu; Qun Wang; Xiaofei Li; Yi Shen; Heng Zhao; Chun Chen; Weimin Mao; Wei Liu; Junfeng Liu; Lanjun Zhang; Haitao Ma; Qiang Li; Yue Yang; Yongyu Liu; Haiquan Chen; Changli Wang
Journal:  Lancet Respir Med       Date:  2018-08-24       Impact factor: 30.700

Review 2.  Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices.

Authors:  Nathan A Pennell; Maria E Arcila; David R Gandara; Howard West
Journal:  Am Soc Clin Oncol Educ Book       Date:  2019-05-17

Review 3.  Trastuzumab containing regimens for early breast cancer.

Authors:  Lorenzo Moja; Ludovica Tagliabue; Sara Balduzzi; Elena Parmelli; Vanna Pistotti; Valentina Guarneri; Roberto D'Amico
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

4.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Authors:  Karen Kelly; Nasser K Altorki; Wilfried E E Eberhardt; Mary E R O'Brien; David R Spigel; Lucio Crinò; Chun-Ming Tsai; Joo-Hang Kim; Eun Kyung Cho; Philip C Hoffman; Sergey V Orlov; Piotr Serwatowski; Jiuzhou Wang; Margaret A Foley; Julie D Horan; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

6.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Authors:  Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

7.  Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Authors:  Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yi Shen; Yong-Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Ke Fei; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Xue-Ning Yang; Qing Zhou; Yi-Long Wu
Journal:  Lancet Oncol       Date:  2017-11-21       Impact factor: 41.316

8.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Authors:  Suresh S Ramalingam; Johan Vansteenkiste; David Planchard; Byoung Chul Cho; Jhanelle E Gray; Yuichiro Ohe; Caicun Zhou; Thanyanan Reungwetwattana; Ying Cheng; Busyamas Chewaskulyong; Riyaz Shah; Manuel Cobo; Ki Hyeong Lee; Parneet Cheema; Marcello Tiseo; Thomas John; Meng-Chih Lin; Fumio Imamura; Takayasu Kurata; Alexander Todd; Rachel Hodge; Matilde Saggese; Yuri Rukazenkov; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2019-11-21       Impact factor: 91.245

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

10.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

Authors:  Yi-Long Wu; Masahiro Tsuboi; Jie He; Thomas John; Christian Grohe; Margarita Majem; Jonathan W Goldman; Konstantin Laktionov; Sang-We Kim; Terufumi Kato; Huu-Vinh Vu; Shun Lu; Kye-Young Lee; Charuwan Akewanlop; Chong-Jen Yu; Filippo de Marinis; Laura Bonanno; Manuel Domine; Frances A Shepherd; Lingmin Zeng; Rachel Hodge; Ajlan Atasoy; Yuri Rukazenkov; Roy S Herbst
Journal:  N Engl J Med       Date:  2020-09-19       Impact factor: 91.245
View more
  2 in total

1.  Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation.

Authors:  Shruti S Sawant; Suyash M Patil; Snehal K Shukla; Nishant S Kulkarni; Vivek Gupta; Nitesh K Kunda
Journal:  Drug Deliv Transl Res       Date:  2021-11-23       Impact factor: 5.671

2.  Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.

Authors:  Christopher A Lemmon; Emily C Zabor; Nathan A Pennell
Journal:  Oncologist       Date:  2022-05-06       Impact factor: 5.837
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.